Tumor-suppressive functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer

Cell Cycle

Volumn 13, Issue 11, 2014, Pages 1798-1810

  Suraneni, Mahipal V ^a,d   Moore, John R ^a   Zhang, Dingxiao ^a   Badeaux, Mark ^a   Macaluso, Marc D ^a   DiGiovanni, John ^b   Kusewitt, Donna ^a   Tang, Dean G ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Flagship Biosciences   (United States)

Author keywords

15 lipoxygenase 2; c Myc; Prostate cancer; RB1CC1; Senescence; Tumor suppression

Indexed keywords

15 LIPOXYGENASE 2 PROTEIN; LAMININ; MYC PROTEIN; PROTEIN; PROTEIN P27; PROTEIN P53; RB1CC1 PROTEIN; REACTIVE OXYGEN METABOLITE; SYNAPSIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84901767910     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28757     Document Type: Article

References (47)

1. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci U S A 1997; 94:6148-52; PMID:9177185; http://dx.doi.org/10.1073/pnas.94.12.6148
2. Kilty I, Logan A, Vickers PJ. Differential characteristics of human 15-lipoxygenase isozymes and a novel splice variant of 15S-lipoxygenase. Eur J Biochem 1999; 266:83-93; PMID:10542053; http://dx.doi.org/10.1046/j.1432-1327. 1999.00818.x
3. Jisaka M, Kim RB, Boeglin WE, Nanney LB, Brash AR. Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin. J Biol Chem 1997; 272:24410-6; PMID:9305900; http://dx.doi.org/10.1074/ jbc.272.39.24410
4. Jisaka M, Kim RB, Boeglin WE, Brash AR. Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. J Biol Chem 2000; 275:1287-93; PMID:10625675; http://dx.doi.org/10.1074/jbc.275.2.1287
5. Shappell SB, Olson SJ, Hannah SE, Manning S, Roberts RL, Masumori N, Jisaka M, Boeglin WE, Vader V, Dave DS, et al. Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 2003; 63:2256-67; PMID:12727848
6. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001; 61:6307-12; PMID:11522616
7. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J, Chandra D, Traag J, Klein RD, Fischer SM, et al. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 2002; 277:16189-201; PMID:11839751; http://dx.doi.org/10.1074/jbc. M111936200
8. Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, Chopra D, Shappell SB, Yang P, Newman RA, Tang DG. Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 2003; 278:25091-100; PMID:12704195; http://dx.doi.org/10.1074/jbc.M301920200
9. Tang DG, Bhatia B, Tang S, Schneider-Broussard R. 15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 2007; 82:135-46; PMID:17164141; http://dx.doi.org/10.1016/j. prostaglandins.2006.05.022
10. Tang S, Bhatia B, Zhou J, Maldonado CJ, Chandra D, Kim E, Fischer SM, Butler AP, Friedman SL, Tang DG. Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene 2004; 23:6942-53; PMID:15247906; http://dx.doi.org/10.1038/sj. onc.1207913
11. Bhatia B, Tang S, Yang P, Doll A, Aumüeller G, Newman RA, Tang DG. Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells. Oncogene 2005; 24:3583-95; PMID:15750631; http://dx.doi.org/10.1038/sj. onc.1208406
12. Bhatia B, Jiang M, Suraneni M, Patrawala L, Badeaux M, Schneider-Broussard R, Multani AS, Jeter CR, Calhoun-Davis T, Hu L, et al. Critical and distinct roles of p16 and telomerase in regulating the proliferative life span of normal human prostate epithelial progenitor cells. J Biol Chem 2008; 283:27957-72; PMID:18662989; http://dx.doi.org/10.1074/jbc. M803467200
13. Bhatia B, Multani AS, Patrawala L, Chen X, Calhoun-Davis T, Zhou J, Schroeder L, Schneider-Broussard R, Shen J, Pathak S, et al. Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int J Cancer 2008; 122:1483-95; PMID:18059027; http://dx.doi.org/10.1002/ijc.23222
14. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007; 46:1-14; PMID:16921491; http://dx.doi.org/10.1002/mc.20255
15. Jack GS, Brash AR, Olson SJ, Manning S, Coffey CS, Smith JA Jr., Shappell SB. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 2000; 31:1146-54; PMID:11014584; http://dx.doi.org/10. 1053/hupa.2000.16670
16. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999; 155:235-45; PMID:10393855; http://dx.doi.org/10.1016/S0002-9440(10)65117-6
17. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000; 141:4698-710; PMID:11108285
18. Suraneni MV, Schneider-Broussard R, Moore JR, Davis TC, Maldonado CJ, Li H, Newman RA, Kusewitt D, Hu J, Yang P, et al. Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence. Oncogene 2010; 29:4261-75; PMID:20514017; http://dx.doi.org/10.1038/ onc.2010.197
19. Chano T, Saji M, Inoue H, Minami K, Kobayashi T, Hino O, Okabe H. Neuromuscular abundance of RB1CC1 contributes to the non-proliferating enlarged cell phenotype through both RB1 maintenance and TSC1 degradation. Int J Mol Med 2006; 18:425-32; PMID:16865226
20. Chano T, Ikebuchi K, Ochi Y, Tameno H, Tomita Y, Jin Y, Inaji H, Ishitobi M, Teramoto K, Nishimura I, et al. RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer. PLoS One 2010; 5:e11404; PMID:20614030; http://dx.doi.org/10.1371/journal.pone.0011404
21. Gan B, Guan JL. FIP200, a key signaling node to coordinately regulate various cellular processes. Cell Signal 2008; 20:787-94; PMID:18036779; http://dx.doi.org/10.1016/j.cellsig.2007.10.021
22. Kontani K, Chano T, Ozaki Y, Tezuka N, Sawai S, Fujino S, Saeki Y, Okabe H. RB1CC1 suppresses cell cycle progression through RB1 expression in human neoplastic cells. Int J Mol Med 2003; 12:767-9; PMID:14533007
23. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4:223-38; PMID:14522256; http://dx.doi.org/10.1016/S1535-6108(03)00197-1
24. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21:1156-67; PMID:18567993; http://dx.doi.org/10.1038/modpathol.2008.111
25. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G, Carnero A, Beach D. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 2005; 65:2179-85; PMID:15781629; http://dx.doi.org/10.1158/0008-5472. CAN-03-4030
26. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999; 3:565-77; PMID:10360173; http://dx.doi.org/10. 1016/S1097-2765(00)80350-0
27. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2:764-76; PMID:12360279; http://dx.doi.org/10.1038/ nrc904
28. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109:321-34; PMID:12015982; http://dx.doi.org/10.1016/S0092-8674(02)00738-9
29. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436:725-30; PMID:16079851; http://dx.doi.org/10.1038/nature03918
30. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64:2270-305; PMID:15026373; http://dx.doi.org/10.1158/0008-5472.CAN-03-0946
31. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66:4011-9; PMID:16618720; http://dx.doi.org/10.1158/0008-5472.CAN-05-3055
32. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22; PMID:20579941; http://dx.doi.org/ 10.1016/j.ccr.2010.05.026
33. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003; 63:3886-90; PMID:12873978
34. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2002; 99:2884-9; PMID:11854455; http://dx.doi.org/10.1073/pnas.042688999
35. Chano T, Ikegawa S, Kontani K, Okabe H, Baldini N, Saeki Y. Identification of RB1CC1, a novel human gene that can induce RB1 in various human cells. Oncogene 2002; 21:1295-8; PMID:11850849; http://dx.doi.org/10.1038/ sj.onc.1205178
36. Mahipal SV, Subhashini J, Reddy MC, Reddy MM, Anilkumar K, Roy KR, Reddy GV, Reddanna P. Effect of 15-lipoxygenase metabolites, 15-(S)-HPETE and 15-(S)-HETE on chronic myelogenous leukemia cell line K-562: reactive oxygen species (ROS) mediate caspase-dependent apoptosis. Biochem Pharmacol 2007; 74:202-14; PMID:17517376; http://dx.doi.org/10.1016/j.bcp.2007.04.005
37. Rao GN, Glasgow WC, Eling TE, Runge MS. Role of hydroperoxyeicosatetraenoic acids in oxidative stress-induced activating protein 1 (AP-1) activity. J Biol Chem 1996; 271:27760-4; PMID:8910370; http://dx.doi.org/10.1074/jbc.271.44.27760
38. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39:41-51; PMID:17173048; http://dx.doi.org/10.1038/ng1935
39. Chano T, Kontani K, Teramoto K, Okabe H, Ikegawa S. Truncating mutations of RB1CC1 in human breast cancer. Nat Genet 2002; 31:285-8; PMID:12068296; http://dx.doi.org/10.1038/ng911
40. Tang Y, Wang MT, Chen Y, Yang D, Che M, Honn KV, Akers GD, Johnson SR, Nie D. Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer. Int J Cancer 2009; 124:1545-51; PMID:19089921; http://dx.doi.org/10.1002/ijc.24118
41. Ikebuchi K, Chano T, Ochi Y, Tameno H, Shimada T, Hisa Y, Okabe H. RB1CC1 activates the promoter and expression of RB1 in human cancer. Int J Cancer 2009; 125:861-7; PMID:19437535; http://dx.doi.org/10.1002/ijc.24466
42. Ochi Y, Chano T, Ikebuchi K, Inoue H, Isono T, Arai A, Tameno H, Shimada T, Hisa Y, Okabe H. RB1CC1 activates the p16 promoter through the interaction with hSNF5. Oncol Rep 2011; 26:805-12; PMID:21637919
43. Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, et al. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer 2011; 128:2843-52; PMID:21128282; http://dx.doi.org/10.1002/ijc.25820
44. Badeaux MA, Jeter CR, Gong S, Liu B, Suraneni MV, Rundhaug J, Fischer SM, Yang T, Kusewitt D, Tang DG. In vivo functional studies of tumor-specific retrogene NanogP8 in transgenic animals. Cell Cycle 2013; 12:2395-408; PMID:23839044; http://dx.doi.org/10.4161/cc.25402
45. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard JR, Pakkenberg B, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988; 96:857-81; PMID:3056461; http://dx.doi.org/10.1111/j.1699-0463.1988.tb00954.x
46. López-Beltrán A, Artacho-Pérula E, Luque-Barona RJ, Roldán-Villalobos R. Nuclear volume estimates in prostatic atypical adenomatous hyperplasia. Anal Quant Cytol Histol 2000; 22:438-44; PMID:11147297
47. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17:211-5; PMID:21240262; http://dx.doi.org/10.1038/nm.2284